ReviewCurrent opinion in immunology2010
IL-33 family members and asthma - bridging innate and adaptive immune responses.
Review in Current opinion in immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 156 citations in OpenAlex.
- The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.Nature communications · 2018Trial
- Reframing paucigranulocytic asthma through genetic endotyping: a hypothesis-generating focus on the 17q21 rs7216389 locus.Current opinion in allergy and clinical immunology · 2026Review
- Emerging Targeted Therapies in Asthma: From Upstream Epithelial Biology to Novel Biologic and Small-Molecule Strategies.Tuberculosis and respiratory diseases · 2026Review
- The immunology of asthma and chronic rhinosinusitis.Nature reviews. Immunology · 2025Review
- Biological mechanisms and therapeutic prospects of interleukin-33 in pathogenesis and treatment of allergic disease.Journal of inflammation (London, England) · 2025Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- Endogenous IL-33 inhibits apoptosis in non-small cell lung cancer cells by regulating BCL2/BAX via the ERK1/2 pathway.Scientific reports · 2025Article
- Association between asthma and cardiovascular disease: evidence from the national health and nutrition examination survey 1999-2018.Frontiers in cardiovascular medicine · 2024Article
- T2-Low Asthma: A Discussed but Still Orphan Disease.Biomedicines · 2023Review
- Mast Cell Cytokines in Acute and Chronic Gingival Tissue Inflammation: Role of IL-33 and IL-37.International journal of molecular sciences · 2022Review
- Review
- Adiponectin restrains ILC2 activation by AMPK-mediated feedback inhibition of IL-33 signaling.The Journal of experimental medicine · 2021Article
- Single-nucleotide polymorphisms and haplotypes in the interleukin-33 gene are associated with a risk of allergic rhinitis in the Chinese population.Experimental and therapeutic medicine · 2020Article
- Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review.Medicina (Kaunas, Lithuania) · 2020Review
- Dual immune functions of IL-33 in inflammatory bowel disease.Histology and histopathology · 2020Review
- IL-33 Mediates Lung Inflammation by the IL-6-Type Cytokine Oncostatin M.Mediators of inflammation · 2020Article
- Genomics of asthma, allergy and chronic rhinosinusitis: novel concepts and relevance in airway mucosa.Clinical and translational allergy · 2020Review
- Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris.Mediators of inflammation · 2020Article
- Serum interleukin-33 as a novel marker for long-term prognosis and recurrence in acute ischemic stroke patients.Brain and behavior · 2019Article
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.International journal of molecular sciences · 2019Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
The discovery of IL-33 as the ligand for the orphan Th2 associated receptor ST2 has uncovered a whole range of different avenues for this pathway. Although the extracellular functions of ST2 as a marker for Th2 cell and mast cell activity were well defined, the complexities of IL-33 regulation, nuclear function and secretion are only just being realised. The well documented expression pattern of ST2 has identified a role for the IL-33/ST2 axis in the classical Th2 cell and mast cell driven pathogenesis of asthma and anaphylaxis. However, the induction of IL-33 expression by environmental or endogenous triggers now suggests a wider role for the pathway during infection, inflammation and tissue damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.